356572-08-2

Basic information

• Product Name: 1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride
• Synonyms: 1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride;3. 1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride;7-Hydroxy MeMantine Hydrochloride;1-AMino-3,5-diMethyl-7-hydroxyadaMantane Hydrochloride;3-AMino-5,7-diMethyltricyclo[3.3.1.13,7]decan-1-ol Hydrochloride;MeMantine IMpurity IV (1-AMino-3-Hydroxy-5,7-DiMethyladaMantane);1-Amino-7-hydroxy-3,5-dimethyl Adamantane Discontinued See: H944700;1-Hydroxy-3-Amino-5,7-Dimethyl Adamantine Hcl
• CAS NO: 356572-08-2
• Molecular Formula: C₁₂H₂₁NO*ClH
• Molecular Weight: 231.76
• EINECS: 1312995-182-4
• Product Categories: Amines;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 356572-08-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 304-306°C
• Boiling Point: 305.2 °C at 760 mmHg
• Flash Point: 138.4 °C
• Appearance: /
• Storage Temp.: -20?C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: 1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride(356572-08-2)
• EPA Substance Registry System: 1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride(356572-08-2)

Safety Data

• Hazardous Substances Data: 356572-08-2(Hazardous Substances Data)

Usage

Description

1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride, also known as a metabolite of Memantine (M218000), is a white solid substance with significant applications in the medical field, particularly for the treatment of neurological disorders.

Uses

Used in Pharmaceutical Industry:
1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride is used as an active pharmaceutical ingredient for the treatment of neurological disorders. It serves as a metabolite of Memantine, which is known for its effectiveness in managing such conditions.
Used in Neurological Treatment:
1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride is used as a therapeutic agent for neurological disorders due to its role as a metabolite of Memantine. It aids in the treatment process by potentially enhancing the effects of Memantine, thus providing relief and improving the quality of life for patients suffering from these disorders.

InChI:InChI=1S/C12H21NO.ClH/c1-9-3-10(2)5-11(13,4-9)8-12(14,6-9)7-10;/h14H,3-8,13H2,1-2H3;1H

Upstream product

• 63971-25-5 3-amino-5,7-dimethyladamantan-1-ol 
• 707-37-9 1,3-dimethyl-5-adamantanol 
• 702-79-4 1,3-dimethyladamantane 
• 351329-87-8 N-(3-hydroxy-5,7-dimethyladamantan-1-yl)acetamide 

Downstream Products

• 356572-22-0 1-(benzyloxycarbonyl)amino-3,5-dimethyl-7-(3-bromopropylcarbonyloxy)adamantine 
• 356572-20-8 1-(benzyloxycarbonyl)amino-3,5-dimethyl-7-hydroxyadamantane 
• 356572-15-1 1,1-dibenzylamino-3,5-dimethyl-7-hydroxy-adamantane 

Relevant articles and documents

Cerium-Catalyzed C-H Functionalizations of Alkanes Utilizing Alcohols as Hydrogen Atom Transfer Agents

Modern photoredox catalysis has traditionally relied upon metal-to-ligand charge-transfer (MLCT) excitation of metal polypyridyl complexes for the utilization of light energy for the activation of organic substrates. Here, we demonstrate the catalytic application of ligand-to-metal charge-transfer (LMCT) excitation of cerium alkoxide complexes for the facile activation of alkanes utilizing abundant and inexpensive cerium trichloride as the catalyst. As demonstrated by cerium-catalyzed C-H amination and the alkylation of hydrocarbons, this reaction manifold has enabled the facile use of abundant alcohols as practical and selective hydrogen atom transfer (HAT) agents via the direct access of energetically challenging alkoxy radicals. Furthermore, the LMCT excitation event has been investigated through a series of spectroscopic experiments, revealing a rapid bond homolysis process and an effective production of alkoxy radicals, collectively ruling out the LMCT/homolysis event as the rate-determining step of this C-H functionalization.

Methods for treating neuropsychiatric disorders with nmda receptor antagonists

The present invention relates to compositions and methods for treating a human patient afflicted with a neuropsychiatric disorder. Specifically, the invention provides for compositions and methods of modulating or antagonizing the activity of neuronal NMD